Compare · ELMD vs MDT
ELMD vs MDT
Side-by-side comparison of Electromed Inc. (ELMD) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELMD and MDT operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $104.82B, about 320.3x ELMD ($327.2M).
- Over the past year, ELMD is up 107.7% and MDT is down 11.0% - ELMD leads by 118.7 points.
- MDT has been more active in the news (4 items in the past 4 weeks vs 1 for ELMD).
- MDT has more recent analyst coverage (25 ratings vs 3 for ELMD).
- Company
- Electromed Inc.
- Medtronic plc.
- Price
- $39.59-1.83%
- $81.89-0.55%
- Market cap
- $327.2M
- $104.82B
- 1M return
- +5.12%
- +3.30%
- 1Y return
- +107.71%
- -10.99%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- AMEX
- NYSE
- IPO
- 2011
- News (4w)
- 1
- 4
- Recent ratings
- 3
- 25
Electromed Inc.
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest ELMD
- Chief Financial Officer Nagel Bradley M. covered exercise/tax liability with 674 shares, decreasing direct ownership by 3% to 18,964 units (SEC Form 4) (for tax liability)
- CEO and President Cunniff James L. exercised 9,700 shares at a strike of $17.25 and sold $354,095 worth of shares (9,700 units at $36.50) (SEC Form 4)
- Chief Financial Officer Nagel Bradley M. exercised 9,601 shares at a strike of $10.50 and sold $428,936 worth of shares (11,801 units at $36.35), decreasing direct ownership by 10% to 19,638 units (SEC Form 4)
- SEC Form SD filed by Electromed Inc.
- Director Skarvan Kathleen exercised 40,000 shares at a strike of $3.82 and sold $1,419,358 worth of shares (40,000 units at $35.48) (SEC Form 4)
- SEC Form 10-Q filed by Electromed Inc.
- Electromed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Electromed, Inc. Announces Record Financial Performance in Fiscal 2026 Third Quarter
- Electromed, Inc. to Report Q3 Fiscal 2026 Financial Results on May 12, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Electromed Inc.
Latest MDT
- A new era for surgery with real-time AI: Medtronic to unveil Touch Surgery™ Aide, the next-generation compute platform for the operating room at Society of Robotic Surgery 2026
- Medtronic to announce financial results for its first quarter of fiscal year 2027
- Medtronic completes acquisition of SPR, expanding patient access to minimally invasive, non-opioid treatment of chronic and acute pain
- SVP, Chief HR Officer Walter Matthew R. sold $257,931 worth of Ordinary Shares (3,102 units at $83.15), decreasing direct ownership by 8% to 35,694 units (SEC Form 4)
- New insider Thompson Kweli claimed ownership of 30,018 units of Ordinary Shares (SEC Form 3)
- SEC Form IRANNOTICE filed by Medtronic plc.
- SEC Form 10-K filed by Medtronic plc.
- Medtronic completes acquisition of Scientia Vascular, seamlessly integrating access and therapeutic portfolios for neurovascular care
- EVP & President Cardiovascular Kiil Harry Skip sold $336,965 worth of Ordinary Shares (4,189 units at $80.44), decreasing direct ownership by 10% to 37,227 units (SEC Form 4)
- EVP & President Cardiovascular Kiil Harry Skip covered exercise/tax liability with 6,817 units of Ordinary Shares, decreasing direct ownership by 14% to 41,416 units (SEC Form 4)